Clinical Trials

MIAMI BEACH, Fla. — Administration of Qelbree for up to 1 year showed similar safety, efficacy and tolerability profiles seen in shorter trials with improvement in ADHD symptoms and executive function, according to a study presented here.

INDIANAPOLIS — For adults with narcolepsy, a switch in treatment to Xywav was safe, efficacious and preferred over treatment with Xyrem on a gram-for-gram basis, according to Wayne Macfadden, MD, in a Healio video from SLEEP 2023.

For this month’s Infectious Disease News cover story, we touched base with experts in transplant medicine and transplant infectious diseases to discuss recent challenges brought on by the pandemic and the country’s organ shortage crisis.

MIAMI BEACH, Fla. — Treatment with KarXT reduced symptom severity for those with schizophrenia and acute psychosis compared with placebo, according to research presented at the American Society of Clinical Psychopharmacology annual meeting.

MIAMI BEACH, Fla. — Adjunctive treatment with aticaprant for those with major depressive disorder and history of antidepressant failure resulted in greater symptom improvement compared with placebo after 6 weeks, a presenter said.

Ethnic and racial disparities exist and persist in many areas of oncology and must be addressed to promote and ensure health equity.

Apellis Pharmaceuticals Inc. announced that its phase 2 MERIDIAN study investigating systemic pegcetacoplan as a treatment for ALS failed to meet efficacy measures of overall function, survival, lung function and muscle strength.

Topline results from a phase 1b/2a study evaluating an investigational therapy for C9orf72-associated ALS and frontotemporal dementia revealed no clinical benefit after 24 weeks of treatment compared with placebo.

Genentech announced positive results from its global phase 2 study evaluating the investigational oral Bruton’s tyrosine kinase inhibitor fenebrutinib in adults with relapsing forms of MS.

CHICAGO — While there is significant interest in the Black community to learn about Parkinson’s disease research and study participation, interventions are needed to reduce recruitment barriers and improve access to information.